Log in

NASDAQ:DMTKDermTech Stock Price, Forecast & News

-0.21 (-1.91 %)
(As of 04/5/2020 04:00 PM ET)
Today's Range
Now: $10.79
50-Day Range
MA: $12.51
52-Week Range
Now: $10.79
Volume11,892 shs
Average Volume60,317 shs
Market Capitalization$160.12 million
P/E RatioN/A
Dividend YieldN/A
DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:DMTK



Sales & Book Value

Annual Sales$3.36 million
Book Value$1.01 per share


Net Income$-19,690,000.00


Market Cap$160.12 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DMTK News and Ratings via Email

Sign-up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter.

DermTech (NASDAQ:DMTK) Frequently Asked Questions

How has DermTech's stock been impacted by COVID-19 (Coronavirus)?

DermTech's stock was trading at $14.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DMTK stock has decreased by 24.9% and is now trading at $10.79. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DermTech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DermTech.

What price target have analysts set for DMTK?

1 equities research analysts have issued 1-year price targets for DermTech's stock. Their forecasts range from $24.00 to $24.00. On average, they anticipate DermTech's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 122.4% from the stock's current price. View analysts' price targets for DermTech.

Has DermTech been receiving favorable news coverage?

Media coverage about DMTK stock has trended very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. DermTech earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutDermTech.

Who are some of DermTech's key competitors?

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include AT&T (T), NovaBay Pharmaceuticals (NBY), Gilead Sciences (GILD), AbbVie (ABBV), Carnival (CCL), Southern (SO), Exxon Mobil (XOM), Crispr Therapeutics (CRSP), Huntington Bancshares (HBAN) and JD.Com (JD).

Who are DermTech's key executives?

DermTech's management team includes the following people:
  • Dr. John D. Dobak, Pres, CEO & Director (Age 53)
  • Mr. Kevin Sun, CFO, Treasurer & Sec.
  • Ms. Claudia Ibarra, Chief Operating Officer (Age 57)
  • Dr. Zuxu Yao, Chief Scientific Officer (Age 57)
  • Ms. Sarah Dennison, VP of Marketing

What is DermTech's stock symbol?

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

How do I buy shares of DermTech?

Shares of DMTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DermTech's stock price today?

One share of DMTK stock can currently be purchased for approximately $10.79.

How big of a company is DermTech?

DermTech has a market capitalization of $160.12 million and generates $3.36 million in revenue each year. DermTech employs 36 workers across the globe. View additional information about DermTech.

What is DermTech's official website?

The official website for DermTech is http://www.dermtech.com/.

How can I contact DermTech?

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company can be reached via phone at 858-450-4222 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel